Claritas Pharmaceuticals, Inc. announced that it has entered into a Strategic Collaboration Agreement with the Salzman Group Ltd. and is in the process of entering into similar agreements with other companies, to expedite the development of the Company’s breakthrough nitric oxide-releasing compound, R-107. To conserve capital and expedite the development of R-107, Claritas is collaborating with the Salzman Group and other companies for the manufacture of R-107, and for the design and completion of clinical studies to demonstrate the safety and efficacy of R-107 in the treatment of COVID-19, influenza, and other viral infections. Under the Collaboration Agreement, Salzman Group will make available to Claritas the full capabilities of Salzman Group, including its expertise in working with nitric oxide and nitric oxide releasing compounds. Salzman Group will also provide a platform of services, including expertise in the manufacture of R-107, design of clinical studies, and consulting services in connection with Claritas’ interactions with regulatory bodies in the USA, Australia, the UK, and the EU.